Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid

Ruoyan Chen,1 Gang Ning,2 Ming-Lang Zhao,1 Matthew G. Fleming,3 Luis A. Diaz,1 Zena Werb,4 and Zhi Liu1

1Department of Dermatology, University of North Carolina, Chapel Hill, North Carolina, USA
2Departments of Cell Biology, Neurobiology, and Anatomy, and
3Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
4Department of Anatomy, University of California, San Francisco, San Francisco, California, USA

Address correspondence to: Zhi Liu, Department of Dermatology, Suite 3100 Thurston Building, University of North Carolina, Chapel Hill, North Carolina 27599, USA.
Phone: (919) 966-0785; Fax: (919) 966-3898; E-mail: zhiliu@med.unc.edu.

Received for publication October 6, 2000, and accepted in revised form August 31, 2001.

Bullous pemphigoid (BP) is an inflammatory subepidermal blistering disease associated with an IgG autoimmune response to the hemidesmosomal protein BP180. Passive transfer of antibodies to the murine BP180 (mBP180) ectodomain triggers a blistering skin disease in mice that depends on complement activation and neutrophil infiltration and closely mimics human BP. In the present study, we show that mast cells (MCs) play a crucial role in experimental BP. Wild-type mice injected intradermally with pathogenic anti-mBP180 IgG exhibited extensive MC degranulation in skin, which preceded neutrophil infiltration and subsequent subepidermal blistering. In contrast, mice genetically deficient in MCs or MC-sufficient mice pretreated with an inhibitor of MC degranulation failed to develop BP. Further, MC-deficient mice reconstituted in skin with MCs became susceptible to experimental BP. Despite the activation of complement to yield C3a and C5a, in the absence of MCs, accumulation of neutrophils at the injection site was blunted. The lack of response due to MC deficiency was overcome by intradermal administration of a neutrophil chemoattractant, IL-8, or by reconstitution of the injection sites with neutrophils. These findings provide the first direct evidence to our knowledge that MCs play an essential role in neutrophil recruitment during subepidermal blister formation in experimental BP.


Introduction

Bullous pemphigoid (BP) is an acquired autoimmune skin disease characterized by autoantibodies against two hemidesmosomal antigens, BP230 (BPAG1) and BP180 (BPAG2), and subepidermal blisters (1). These anti-hemidesmosomal autoantibodies can be detected, along with complement proteins, bound to the dermal-epidermal junction (DEJ) of perilesional skin. In the skin lesions of these patients, basal keratinocytes detach from the underlying dermis at the level of the lamina lucida, leading to subepidermal blistering (1, 2). Eosinophils (3, 4), neutrophils (5), lymphocytes (6), monocyte/macrophages (7, 8), and mast cells (MCs; 7, 9) are present in the upper dermis of lesional areas in patients with BP. Interestingly, MC degranulation is a feature of BP (7, 9). Chemoattractants from MCs, including eosinophilic/neutrophilic chemoattractant factors and histamine, are present at high concentrations in BP blister fluids (10, 11). Similar skin lesions are observed in the pregnancy-associated nonviral disorder herpes gestationis (12). These observations imply that MCs may play a role in blister formation.

We have used an experimental model of BP that involves the passive transfer of anti-mBP180 antibodies into neonatal BALB/c mice to reproduce the key immunopathological features of this human autoimmune disease: IgG and complement deposition at the DEJ, inflammatory infiltration of the upper dermis, and subepidermal blistering (13). The pathogenicity of anti-mBP180 antibodies depends on complement activation (14) and polymorphonuclear leukocyte (PMN) recruitment (15). In the present study, we have investigated the role of MCs in experimental BP using mice genetically deficient in MCs.

Methods

Laboratory animals. Breeding pairs of MC-deficient WCB6F1-MgfSl/MgfSl-d (referred to as MgfSl/MgfSl-d), MC-deficient WBB6F1-Kitw/Kitw– (referred to as Kitw/Kitw–), and the congenic MC-sufficient (MC+/+) littermates (16) and C5-deficient B10-D2-OSN (C5–) and their matched normal control B10-D2-NSN (C5+) mice were purchased from The Jackson Laboratory (Bar Harbor, Maine, USA) and maintained at the Medical College of Wisconsin Animal Resource Center and the University of North Carolina at Chapel Hill Animal facility. The MC deficiency in MgfSl/MgfSl-d and Kitw/Kitw– mice are caused by distinct mutations in MC growth factor and c-Kit, respectively (16). Neonatal mice (24–36 hours old, 1.4–1.6 g) were used for passive transfer experiments.

Preparation of pathogenic rabbit anti-mouse IgG. The preparation of recombinant mBP180 and the immunization of rabbits were performed as described previ-
ously (13). The titers of rabbit anti-mBP180 antibodies in the rabbit sera and in the purified IgG fractions were assayed by indirect immunofluorescence (IF) using mouse skin cryosections as substrate (13). The pathogenicity of these IgG preparations were tested by passive transfer experiments, as described below.

**Induction of experimental BP and animal evaluation.** A 50-µl dose of sterile IgG in PBS was administered to neonatal mice by intradermal injection (2.5 mg IgG per gram of body weight) as described previously (13, 15). The skin of neonatal mice from the test and control groups was examined 12 hours after the IgG injection. The extent of cutaneous disease was scored as follows: (−), no detectable skin disease; 1+, mild erythematous reaction with no evidence of the “epidermal detachment” sign (this sign was elicited by gentle friction of the mouse skin, which, when positive, produced fine, persistent wrinkling of the epidermis); 2+, intense erythema and epidermal detachment sign involving 10–50% of the epidermis in localized areas; and 3+, intense erythema with frank epidermal detachment sign involving more than 50% of the epidermis. The animals were then killed, and skin and serum specimens were obtained. Skin sections were taken for light microscopy (hematoxylin and eosin [H&E] staining) and for direct IF analysis to detect rabbit IgG and mouse C3 deposition at the basement membrane zone (BMZ). Sera of injected animals were used for indirect IF assay to determine the circulating titers of anti-mBP180 IgG. Direct and indirect IF analyses were performed as described previously (13). Monospecific FITC-conjugated goat anti-rabbit IgG was purchased from Kirkegaard & Perry Laboratories Inc. (Gaithersburg, Maryland, USA); monospecific goat anti-mouse C3 was purchased from Cappel Laboratories (Durham, North Carolina, USA).

**Quantification of PMN accumulation at the skin site.** Myeloperoxidase (MPO) activity in skin sites of the injected animals was assayed as a measure of PMN infiltration as described elsewhere (17, 18). A standard reference curve was established using purified MPO (Athens Research and Technology Inc., Athens, Georgia, USA). The skin samples were extracted by homogenization in an extraction buffer containing 0.1 M Tris-Cl (pH 7.6), 0.15 M NaCl, and 0.5% hexadecyl trimethylammonium bromide. MPO activity in the supernatant fraction was measured by the change in optical density at 460 nm resulting from decomposition of H2O2 in the presence of o-dianisidine. MPO content was expressed as units of MPO activity per milligram of protein. Protein concentrations were determined by the Bio-RAD dye-binding assay (Bio-Rad Laboratories Inc., Hercules, California, USA) using BSA as a standard.

**Quantification of MCs and MC degranulation.** MCs and MC degranulation in skin samples were quantified according to Wershil et al. (19) with modification. Briefly, lesional and nonlesional skin sections of IgG-injected mice were fixed in 10% formalin. Paraffin sections (5 µm thick) were prepared and stained with toluidine blue and H&E. The total number of MCs was counted and classified as degranulated (>10% of the granules exhibiting fusion or discharge) or normal in five fields under a light microscope as described previously. The results were expressed as percentage of MC degranulating.

**Electron microscopic analysis of MC morphology.** The skin samples were dissected from the injected sites of the test and control animals and immersed in a fixative of 2% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2). The tissue blocks were post-fixed with OsO4, and then dehydrated with a series of graded ethanol. Thin sections were contrasted with uranyl acetate and lead citrate and examined with a Hitachi-600 transmission electron microscope (Hitachi Instruments Inc., San Jose, California, USA) at 75 KV.

**In vivo inhibition of MC degranulation.** Neonatal wild-type mice were injected intradermally with pathogenic IgG (2.5 mg per gram of body weight) in the absence or presence of cromolyn sodium (Sigma Chemical Co., St. Louis, Missouri, USA) (10 µg per gram of body weight), an MC degranulation inhibitor (20, 21). The animals were examined for clinical blisters 12 hours after IgG injection, and the skin sections were analyzed by IF, H&E, and toluidine blue staining. Skin PMN infiltration was quantified by MPO assay.

**PMN isolation.** Mouse PMNs were isolated from heparinized blood by dextran sedimentation followed by separation on a density gradient as described previously (22). Red blood cells were removed from the cell preparation by hypotonic lysis in 0.2% NaCl. PMNs were washed and resuspended in cold PBS/10 mM glucose, counted in a hemocytometer, and adjusted to a concentration of 1 × 10⁷ cells/ml. PMN purity of the final cell preparation was consistently more than 96% as determined by cell-lysostop and LeukoStat staining (Fisher Diagnostics, Orangeburg, New York, USA). The viability of the neutrophils was >96% as determined by trypan blue exclusion.

**Intradermal injection of PMNs.** PMNs were purified from MC-deficient and MC−/− mice. MC-deficient mice were injected intradermally with pathogenic anti-mBP180 IgG (2.5 mg per gram of body weight per 50 µl PBS). Two hours later, these mice were injected with 5 × 10⁵ PMNs intradermally (in 50 µl of PBS/10 mM glucose) at the same site (23). The animals were analyzed 12 hours after the IgG injections, as described above.

**IL-8 pretreatment of MC-deficient mice.** Recombinant human IL-8 (hIL-8; R&D Systems Inc., Minneapolis, Minnesota, USA) was stored at 1 mg/ml in sterile PBS. A single intradermal injection of IL-8 (50 ng in 50 µl PBS) or an equivalent amount of BSA was given to neonatal MC-deficient mice, followed by intradermal injection of rabbit anti-mBP180 IgG (2.5 mg per gram of body weight in 50 µl) 1 hour later (15). Control animals received an equivalent amount of normal rabbit IgG, in place of the anti-mBP180 IgG. The animals were analyzed 12 hours after the IgG injections, as described above.

**MC reconstitution.** Kitw/Kitw−/− mice were repaired of their MC deficiency selectively and locally by the injection of
growth factor–dependent bone marrow–derived cultured MCs into the skin (24, 25). Briefly, femoral bone marrow cells from congenic MC+/+ mice were maintained in vitro for 4 weeks in RPMI 1640 complete medium (Life Technologies Inc., Grand Island, New York, USA) supplemented with 20% WEHI-3–conditioned medium until MCs represented more than 95% of the total cells as determined by toluidine blue staining and flow cytometry analysis using antibodies specific for MC cell-surface markers FcεRI, c-Kit, and CD13 (25). Murine IgE and rat anti-mouse IgE were purchased from Southern Biotechnology Associates (Birmingham, Alabama, USA). FITC-labeled rat anti-mouse c-Kit and FITC-labeled rat anti-mouse CD13 were obtained from BD PharMingen (San Diego, California, USA). MCs (1 × 10^6 in 20 µl of medium) were injected intradermally into the right ears of MC-deficient mice. Media alone (20 µl) were injected intradermally into the left ears of the same mice as negative control. This procedure selectively and locally reconstitute dermal MC population without systemic effects (24). To confirm MC reconstitution, skin sections from MC-injected sites were stained by toluidin blue. Ten weeks after adoptive transfer of MCs, both ears of the mice were injected intradermally with pathogenic anti-BP180 IgG (2 mg/20 µl/site). Twenty-four hours later, ear skin biopsies were obtained and analyzed by H&E, toluidine blue staining, and MPO enzyme assay as described above.

**Figure 2**
Clinical and immunohistological analysis of neonatal MC-deficient and -sufficient mice injected with pathogenic anti-mBP180 IgG. The anti-mBP180 IgG (2.5 mg/g body weight) induced extensive blistering disease in MC-sufficient (+/+ ) mice (a). The skin of these animals showed linear deposition of rabbit IgG (b) and murine C3 (c) at the BMZ, as determined by direct IF. Toluidine blue staining revealed epidermal-dermal separation with MC degranulation (d). In contrast, MC-deficient (MgfSl/MgfSl) mice injected intradermally with pathogenic IgG showed no evidence of skin disease (e). Direct IF demonstrated BMZ deposition of rabbit IgG (f) and murine C3 (g). Toluidine blue staining showed no epidermal-dermal separation and absence of MCs (h). d, dermis; e, epidermis; v, vesicle; black arrow in a and e, site of clinical blister; white arrow, site of antibody labeling; black arrow in d and h, site of BMZ. ×400. Inset in d is a lower-magnification micrograph showing the edge of a subepidermal vesicle. ×100.
Effect of MC reconstitution on neutrophil infiltration and subsequent subepidermal blistering in pathogenic anti-BP180 IgG-injected MC-deficient mice. Neutrophil infiltration and blister formation were determined in the left (MC-deficient) (middle bar) and right (MC-reconstituted) (bottom bar) ears of Kit+/Kit-/- mice that underwent local reconstitution of the right ear with 1 x 10^6 bone marrow-derived MC+/+ MCs 10 weeks before pathogenic IgG injection (2 mg/ear). MC+/+ littermates (top bar) were also injected with the same dose of IgG in the ear as positive control (see Methods for details). Significantly elevated levels of MPO activity (mean ± SEM) were seen in the right ear compared with the left ear of Kit+/Kit-/- mice. Like MC-/- mice, the right but not the left ear skin sections exhibited dermal-epidermal separation as determined by H&E staining. MPO activity at 0 hours was 0.07 ± 0.01 for MC-deficient and 0.09 ± 0.02 (OD460nm/mg protein) for MC+/- mice. (n = 6 for each group.) *P < 0.01, top vs. middle bar.

Table 1: The role of MCs in BP blister formation

<table>
<thead>
<tr>
<th>Host mice</th>
<th>Ig injected</th>
<th>Treatment</th>
<th>Number of mice</th>
<th>Disease activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>+/-</td>
<td>Control IgG</td>
<td>–</td>
<td>5</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Pathogenic IgG</td>
<td>–</td>
<td>12</td>
<td>3+</td>
</tr>
<tr>
<td></td>
<td>Pathogenic IgG</td>
<td>Cromolyn</td>
<td>5</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Pathogenic IgG</td>
<td>5 x 10^5 PMNs</td>
<td>5</td>
<td>3+</td>
</tr>
<tr>
<td></td>
<td>Pathogenic IgG</td>
<td>hIL-8</td>
<td>5</td>
<td>3+</td>
</tr>
<tr>
<td></td>
<td>Pathogenic IgG</td>
<td>hIL-8 + cromolyn</td>
<td>5</td>
<td>3+</td>
</tr>
<tr>
<td>Kit+/Kit-/-</td>
<td>Pathogenic IgG</td>
<td>Medium (left ears)</td>
<td>6</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Pathogenic IgG</td>
<td>1 x 10^6 MCs (right ears)</td>
<td>6</td>
<td>+</td>
</tr>
</tbody>
</table>

*Neonatal MC-deficient (MgfSl/MgfSl-d and Kit+/Kit-) and MC-sufficient control (MC+/-) mice were injected intradermally with either control IgG (R50) or pathogenic anti-mBP180 antibody (R621) (2.5 mg per gram of body weight). The MC degranulation inhibitor cromolyn sodium (10 µg/g body weight) or hIL-8 (50 ng/g body weight) was given intradermally. Purified mouse PMNs (5 x 10^6 cells/50 µl) from MgfSl/MgfSl-d or MC+/- mice were given intradermally 2 hours after IgG injection. For MC reconstitution experiments, 1 x 10^6 MCs from MC+/- mice were injected into the right ears of Kit+/Kit-/- mice (6 weeks old). A total of 20 µl of MC culture medium was injected into the left ears of the same mice as negative control. Ten weeks later, the mice were challenged with pathogenic IgG (2 mg/site) and examined 24 hours after IgG injection. *Disease activity was scored as described in Methods.
Anti-mBP180 IgG failed to trigger the skin lesions in MC-deficient mice (data not shown). Toliudine blue staining confirmed the MC deficiency in these animals (d and f).

Experimental BP in MC-deficient mice reconstituted with normal PMNs. Pathogenic rabbit anti-mBP180 IgG (intradermal injection, 2.5 mg/g body weight) induced skin blisters in MC-sufficient (+/+) (bar 1) or MC-deficient MgfSl/MgfSl-d mice (e), but R621 IgG triggered the skin disease in MgfSl+/MgfSl-d mice reconstituted with PMNs from MC+/+ mice (e) or MC-deficient mice (data not shown). Toliudine blue staining confirmed the MC deficiency in these animals (d and f).

Pathogenic anti-mBP180 IgG induces subepidermal blistering in MC-deficient mice reconstituted with PMNs from MC-deficient mice or by intradermal injection of the neutrophil chemoattractant IL-8. If the major function of MCs in experimental BP is to recruit PMNs from circulation to the dermis of the MC-deficient mice should circumvent the requirement for MCs for disease phenotype. This is exactly what we observed when we injected MC-deficient mice with pathogenic IgG and reconstituted them with mouse PMNs. The MC-deficient mice reconstituted with 5 x 10^6 PMNs from wild-type mice (n = 5) developed subepidermal blisters 12 hours after IgG injection (Figure 4). The MC-deficient mice reconstituted with 5 x 10^6 PMNs from MC-deficient mice (n = 5) also became susceptible to pathogenic anti-mBP180 IgG, with a similar disease score indicating that PMNs are normal in MC deficiency (Table 1). In addition, MC-deficient mice (n = 5) given an intradermal injection of IL-8 before, or coincident with, the treatment with anti-mBP180 IgG, developed extensive blisters 12 hours later (Figure 5 and Table 1). The skin of these mice showed typical subepidermal separation and morphological and biochemical evidence of neutrophilic infiltration of the dermis (Figure 5). The mean MPO activity level in skin extracts of MC-deficient mice injected with anti-mBP180 IgG and IL-8 was 1.14 ± 0.18 OD 460nm/mg protein (Figure 5), compared with 0.29 ± 0.02 (P < 0.01) for skin from the mice injected only with anti-mBP180 IgG. Taken together, these results clearly demonstrate that MCs mainly participate in PMN recruitment in experimental BP.

Figure 5
In vivo reconstitution of PMNs at the tissue site by intradermal injection of IL-8 restores the pathogenic effect of anti-BP180 IgG in neonatal MC-deficient mice. MC-sufficient (+/+) (bar 1) or MC-deficient MgfSl+/MgfSl-d mice (bars 2–6) were injected intradermally with either pathogenic anti-mBP180 IgG alone (bars 1 and 4), control rabbit IgG alone (bar 2), hIL-8 alone (bar 3), or IgG plus hIL-8 (bars 5 and 6). MC-deficient mice injected with IL-8 and anti-mBP180 IgG (bar 5), but not the control rabbit IgG (bar 6), developed subepidermal blisters. The IgG dose was 2.5 mg/g body weight. Doses for IL-8 was 50 ng/mouse. Tissue MPO activity (mean ± SEM) in skin at the injection site was determined 12 hours after IgG administration. Each group of mice (n = 5) without injection yielded an average of MPO activity of 0.08 ± 0.02 OD 460nm/mg protein. *P < 0.01, Student’s t-test for paired samples (bar 4 versus bar 5). See Methods for details.
MC-deicient mice with cromolyn followed by injection of pathogenic IgG plus IL-8. There was no difference in PMN influx and disease scores between MC-deficient mice coinjected with pathogenic IgG and IL-8 with or without cromolyn pretreatment (Table 1). Because initial PMN recruitment is impaired in both MC-deficient mice and in MC-sufficient mice treated with cromolyn sodium, MCs appear to play a key role in early steps of recruiting PMNs as a consequence of degranulation.

**Complement is required for MC degranulation and PMN recruitment.** The requirement for neutrophil recruitment requires MCs. Complement is required for blister formation. Complement fragments can both induce PMN chemotaxis and MC degranulation (26). Because complement was still present at the BMZ in MC-deficient mice, we next determined whether complement activation was a key element for MC degranulation or PMN recruitment. As a genetic test of whether MC-activation was a key element for MC degranulation or PMN recruitment, we have previously demonstrated that subepidermal blister formation triggered by anti-mBP180 IgG. Pathogenic IgG failed to induce disease phenotype in MC-deficient mice. Not only did MC degranulate extensively in experimental BP (81% at the peak), but this degranulation was necessary for blistering. We have previously demonstrated that subepidermal blistering depends on complement activation (14).

**Discussion**

The aim of the present study was to assess the role of MCs in the pathogenesis of subepidermal blister formation in a mouse model of BP. The presence and degranulation of MCs at the BP lesional sites were first reported by Wintroub et al. in 1978 (7) and subsequently confirmed by other investigators (9, 27, 28). However, until our study, the functional significance of MCs in BP remained obscure. In this report, we find that the major role for MCs is as mediators in PMN recruitment and, thus, in subepidermal blister formation triggered by anti-mBP180 IgG. Pathogenic IgG failed to induce disease phenotype in MC-deficient mice. Not only did MC degranulate extensively in experimental BP (81% at the peak), but this degranulation was necessary for blistering. We have previously demonstrated that subepidermal blistering depends on complement activation (14).
and neutrophil infiltration into the dermis (15). We now found that complement activation is required for MC degranulation. Injection of cromolyn sodium, which inhibits MC degranulation, prevented PMN recruitment and, subsequently, subepidermal blistering.

In these studies, we used two different strains of MC-deficient mice caused by distinct mechanisms: $\text{Mgf}^{\text{b/b}}/\text{Mgf}^{\text{b/b}}$ mice have mutations in the c-Kit ligand MC growth factor (stem cell factor) and $\text{Kit}^{\text{w/w}}/\text{Kit}^{\text{w/w}}$ mice have mutations in c-Kit. Owing to the nature of the mutations, transplantation of congenic $\text{MC}^{+/+}$ MCs repairs the MC deficiency of $\text{Kit}^{w/}\text{Kit}^{w+}$, but not $\text{Mgf}^{b/b}/\text{Mgf}^{b/b}$ mice (16, 29). We found that both strains were resistant to the pathogenic activity of anti-BP180 IgG, independently (16, 29). We found that both strains were resistant to the pathogenic activity of anti-BP180 IgG, independently (16, 29). We now found that both strains were resistant to the pathogenic activity of anti-BP180 IgG, independently (16, 29). We now found that both strains were resistant to the pathogenic activity of anti-BP180 IgG, independently (16, 29).

MC degranulation precedes PMN infiltration and subsequent DEJ separation. Our results show a significant reduction in PMN infiltration both in the early and late stages of the disease process in MC-deficient mice. Blocking MC degranulation significantly reduced PMN recruitment into the skin and completely abolished experimental BP. Furthermore, when a potent PMN chemoattractant, such as IL-8, was coadministered with the anti-mBP180 antibodies, the MC-deficient mice showed both clinical and histological evidence of neutrophil infiltration of the dermis and subepidermal blistering. Taken together, these findings provide the first in vivo evidence that subepidermal blistering induced by pathogenic anti-mBP180 antibodies depends on MCs, which, by degranulation step, play an essential role in recruiting neutrophils to the target tissue.

C3a and C5a have been widely used to stimulate activation and chemotaxis of PMNs (26). However, C5a also can induce MC degranulation (26). In human BP studies, complement components are fixed on the DEJ and are present in the blister fluid (1). Indeed, mice that are genetically deficient in C5 are resistant to experimental BP and show a significant reduction in PMN infiltration into the dermis relative to C5-sufficient controls (14). In the present study, we found that C5 deficiency completely abolished MC degranulation. These data suggest that a key function of complement system is MC activation triggered by pathogenic anti-BP 180 IgG. However, C5a also can induce PMN chemotaxis (26). From our data showing anti-mBP180 IgG-injected MC-deficient mice had 31% of MPO activity, and MC-deficient mice treated with cromolyn sodium had 38% of MPO activity of diseased mice, we can conclude that MC degradation–dependent mechanism accounts for approximately two thirds of the PMN infiltration into the skin. Thus anti-mBP180 IgG triggers PMN infiltration by both an MC-dependent and an MC-independent pathway. But how do MCs regulate PMN infiltration? MCs can produce a variety of mediators such as leukotrienes, platelet-activating factor, and cytokines that contribute directly or indirectly to PMN recruitment (30, 31). In fact, high levels of histamine, leukotriene B4, IL-1, -2, -5, and -6, and TNF-α are present in BP blister fluids (11, 32–37). The MC-independent pathway probably involves direct activation of PMNs by the complement fragments activated by interaction between anti-mBP180 and its target antigen.

Support for our conclusion that the major role of MCs in experimental BP is as mediators of PMN infiltration comes from our findings that artificially recruiting PMNs to the dermis of MC-deficient mice circumvents the requirement for MCs for disease phenotype. These data are consistent with our previous observations that subepidermal blistering depends on PMNs, which are recruited into the skin site and, upon activation, release neutrophil elastase (38) and gelatinase B to damage DEJ (23). However, it is also possible that MCs contribute to other aspects of the pathogenic process. MCs could contribute to tissue damage directly by cleaving structural proteins in the DEJ or indirectly by activating gelatinase B in experimental BP. MCs contain numerous proteolytic enzymes (30). Activation and degranulation of MCs are associated with matrix degradation (39). The MC-specific serine protease MCP-4 (chymase) can activate gelatinase B, a protease required for BP (40).

It is known that our present studies, however, have not yet uncovered the mechanisms by which anti-BP180 IgG- and C′-dependent MC degranulation is linked to the neutrophils infiltration in experimental BP.

In summary, our present study provides direct evidence that subepidermal blistering triggered by anti-mBP180 antibodies is MC dependent. MCs participate in acute and chronic inflammatory responses (28, 41–44). Our current data extend their function to an autoimmune blistering disease, BP. MC products, such as TNF-α and MC tryptase, have been linked directly to neutrophils influx (45–47). Further investigations will be necessary to identify the MC-released molecule(s), which play a direct role in recruiting neutrophils downstream of anti-BP180 IgG- and complement-dependent MC degranulation, so we can better understand the immunopathogenesis of these complex reactions in experimental BP. Inhibition of MC degranulation could be a new therapeutic strategy for BP. These findings may have significant implications for other autoimmune subepidermal blistering disorders in which an anti-BP180 immune response and MCs have been implicated, such as cicatricial pemphigoid, linear IgA bullous dermatosis, lichen planus pemphigoid, epidermolysis bullosa acquisita, and lupus skin conditions (48–53).

Acknowledgments
This work was supported in part by US Public Health Service grants (R29 AI40768 to Z. Liu; R01 AR-32599 and R37-AR32081 to L.A. Diaz; and P60 AR-20684 and P01 CA-72006 to Z. Werb), grants from the NIH, and a VA Merit Review Grant (to L.A. Diaz).


